Registry Following Advanced Ovarian and Endometrial Cancer Patients in Germany
Collects treatment, disease course and patient-reported information in adults with advanced ovarian or endometrial cancer.
Plain-language title generated from the registry record
Registry title: Registry Platform Ovarian and Endometrial Cancer
Key facts
- Where
- Multiple Locations, GermanySee the site
Where in Germany
- Multiple sites all over germanyMultiple Locations, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT05129969
- Record updated
- 28 January 2026
- Original description
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.Read full original descriptionShow less
SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.
Inclusion: Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):; patients with FIGO stage IIb-IV OC who are starting systemic treatment or; patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease; Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy; Signed and dated informed consent (IC):; Patients participating in PRO module: IC before first therapy cycle; Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle.
Exclusion: newly diagnosed early-stage OC (FIGO stage I-IIa); Low grade mOC OR; Early-stage EC (FIGO stage I-II).